

Consensus or Controversy? Documenting and Discussing Investigators' Approaches to the Management of Colorectal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following outcomes best represents results of the Phase III CALGB/SWOG-80702 trial evaluating the addition of celecoxib to standard adjuvant therapy for patients with Stage III colon cancer?
 - a. No significant disease-free survival (DFS) improvement among patients with and without detectable circulating tumor DNA (ctDNA)
 - b. Significant DFS improvement among patients with detectable ctDNA
 - c. Significant DFS improvement among patients with and without detectable ctDNA
2. A Phase II study of neoadjuvant dostarlimab for 49 patients with previously untreated, unresected locally advanced mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer reported which of the following efficacy outcomes?
 - a. No clinical complete responses (cCRs)
 - b. 33% cCR rate
 - c. 66% cCR rate
 - d. 100% cCR rate
3. Which of the following drug descriptions best characterizes the mechanism of action of zanzalintinib?
 - a. MEK-targeting tyrosine kinase inhibitor (TKI)
 - b. Selective HER2-targeting TKI
 - c. Selective VEGF2-targeting TKI
 - d. Multitargeted TKI
4. The Phase III AZUR-2 trial is investigating the efficacy and safety of dostarlimab in which of the following settings?
 - a. After neoadjuvant chemoradiation therapy for Stage II to Stage IV rectal cancer
 - b. In combination with chemotherapy after surgery for Stage III microsatellite-stable colon cancer
 - c. As perioperative therapy for Stage III dMMR/MSI-H resectable colon cancer
 - d. In combination with chemotherapy as first-line therapy for metastatic colorectal cancer (mCRC)
5. Which of the following regimens demonstrated a significant improvement in overall survival in comparison to regorafenib monotherapy for patients with previously treated mCRC not dMMR/MSI-H in the Phase III STELLAR-303 study?
 - a. Trifluridine/tipiracil with bevacizumab
 - b. Zanzalintinib with atezolizumab
 - c. Regorafenib with bevacizumab
 - d. Cabozantinib with nivolumab